The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus
Background. Diabetes mellitus is often accompanied by dyslipidemia. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), have been reported to exert effects on lipid, while the results remain controversial. This study i...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2024-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2024/2431441 |
| _version_ | 1797221993457647616 |
|---|---|
| author | Simo Liu Jing Ke Xiaotong Feng Zongwei Wang Xin Wang Longyan Yang Dong Zhao |
| author_facet | Simo Liu Jing Ke Xiaotong Feng Zongwei Wang Xin Wang Longyan Yang Dong Zhao |
| author_sort | Simo Liu |
| collection | DOAJ |
| description | Background. Diabetes mellitus is often accompanied by dyslipidemia. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), have been reported to exert effects on lipid, while the results remain controversial. This study is aimed at exploring the effect of SGLT2 inhibitor canagliflozin on lipid profile. Methods. This study was a single-center, open-label, nonrandomized, prospective study. Metformin (500 mg three times per day) or canagliflozin (100 mg, once daily) was administered for 12 weeks. Fasting blood samples were collected before and 12 weeks after treatment. Serum lipid profile levels and angiopoietin-like protein 3 (ANGPTL3) were determined. In animal experiment, C57BL/6 J mice were divided into three groups including control, STZ + HFD, and STZ + HFD + canagliflozin. Lipid profile and plasma ANGPTL3 level were measured after 12 week’s treatment. Moreover, the expression of ANGPTL3 was detected in the liver tissues. Results. There was a decreased trend in low-density lipoprotein cholesterol (LDL-c) and triglycerides (TG) after canagliflozin treatment, while canagliflozin significantly increased high-density lipoprotein cholesterol (HDL-c) level and decreased plasma ANGPTL3 level. In addition, the expression of ANGPTL3 in liver tissues decreased obviously in diabetic mice with canagliflozin treatment. Conclusions. Canagliflozin increases HDL-c level and suppresses ANGPTL3 expression in patients with T2DM and diabetic mice. The reduction of ANGPTL3 may contribute to the increase of HDL-c. However, the specific mechanism needs further research. This trial is registered with ChiCTR1900021231. |
| first_indexed | 2024-04-24T13:14:16Z |
| format | Article |
| id | doaj.art-b7006944054344d9b774f758a19ec6c5 |
| institution | Directory Open Access Journal |
| issn | 2314-6753 |
| language | English |
| last_indexed | 2024-04-24T13:14:16Z |
| publishDate | 2024-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj.art-b7006944054344d9b774f758a19ec6c52024-04-05T00:00:04ZengHindawi LimitedJournal of Diabetes Research2314-67532024-01-01202410.1155/2024/2431441The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes MellitusSimo Liu0Jing Ke1Xiaotong Feng2Zongwei Wang3Xin Wang4Longyan Yang5Dong Zhao6Center for Endocrine Metabolism and Immune DiseasesCenter for Endocrine Metabolism and Immune DiseasesCenter for Endocrine Metabolism and Immune DiseasesCenter for Endocrine Metabolism and Immune DiseasesInstitute of Medical GenomicsCenter for Endocrine Metabolism and Immune DiseasesCenter for Endocrine Metabolism and Immune DiseasesBackground. Diabetes mellitus is often accompanied by dyslipidemia. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), have been reported to exert effects on lipid, while the results remain controversial. This study is aimed at exploring the effect of SGLT2 inhibitor canagliflozin on lipid profile. Methods. This study was a single-center, open-label, nonrandomized, prospective study. Metformin (500 mg three times per day) or canagliflozin (100 mg, once daily) was administered for 12 weeks. Fasting blood samples were collected before and 12 weeks after treatment. Serum lipid profile levels and angiopoietin-like protein 3 (ANGPTL3) were determined. In animal experiment, C57BL/6 J mice were divided into three groups including control, STZ + HFD, and STZ + HFD + canagliflozin. Lipid profile and plasma ANGPTL3 level were measured after 12 week’s treatment. Moreover, the expression of ANGPTL3 was detected in the liver tissues. Results. There was a decreased trend in low-density lipoprotein cholesterol (LDL-c) and triglycerides (TG) after canagliflozin treatment, while canagliflozin significantly increased high-density lipoprotein cholesterol (HDL-c) level and decreased plasma ANGPTL3 level. In addition, the expression of ANGPTL3 in liver tissues decreased obviously in diabetic mice with canagliflozin treatment. Conclusions. Canagliflozin increases HDL-c level and suppresses ANGPTL3 expression in patients with T2DM and diabetic mice. The reduction of ANGPTL3 may contribute to the increase of HDL-c. However, the specific mechanism needs further research. This trial is registered with ChiCTR1900021231.http://dx.doi.org/10.1155/2024/2431441 |
| spellingShingle | Simo Liu Jing Ke Xiaotong Feng Zongwei Wang Xin Wang Longyan Yang Dong Zhao The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus Journal of Diabetes Research |
| title | The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus |
| title_full | The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus |
| title_fullStr | The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus |
| title_full_unstemmed | The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus |
| title_short | The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus |
| title_sort | effect of canagliflozin on high density lipoprotein cholesterol and angiopoietin like protein 3 in type 2 diabetes mellitus |
| url | http://dx.doi.org/10.1155/2024/2431441 |
| work_keys_str_mv | AT simoliu theeffectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT jingke theeffectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT xiaotongfeng theeffectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT zongweiwang theeffectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT xinwang theeffectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT longyanyang theeffectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT dongzhao theeffectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT simoliu effectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT jingke effectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT xiaotongfeng effectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT zongweiwang effectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT xinwang effectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT longyanyang effectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus AT dongzhao effectofcanagliflozinonhighdensitylipoproteincholesterolandangiopoietinlikeprotein3intype2diabetesmellitus |